This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Explore Content

ReFacto AF (moroctocog alfa) Prescribing Information for Great Britain click here. ReFacto AF (moroctocog alfa) Prescribing Information for Northern Ireland click here.
Adverse event reporting information can be found at the bottom of the page.


​​​​​​ReFacto AF® (moroctocog alfa) is indicated for the treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency). ReFacto AF® is appropriate for use in adults and children of all ages, including newborns. ReFacto AF® does not contain von Willebrand factor, and hence is not indicated in von Willebrand's disease.1

Patient satisfaction with the FuseNGo

The FuseNGo device is a pre-filled syringe that allows all-in-one reconstitution and administration of ReFacto AF®. Studies show that patients are satisfied with administration of factor VIII with the FuseNGo.2,3​​​​​​​

Patient reported outcomes

The FuseNGo was developed for ease of administration, containing separate chambers for the powder and solution (uniformly 4 mL).1–3

​​​​​​​Patients preferred the ReFacto AF® FuseNGo reconstitution vs. other routine devices tested:2†,3‡

Satisfied with administration

Preferred device

Product most likely to be used prophylactically

Achieved high adherence scores

In one study, when patients considered their experience with the ReFacto AF® FuseNGo device, significant increases in the proportion of positive responses were seen for all four questions regarding ease of use compared with the current treatment.2​​​​​​​

Adapted from Di Minno G et al. Patient Preference and Adherence 2019:13 233–240.2

Easy to use

More patients found ease of preparation, storage, disposal of needles and syringes, and use of treatment to be convenient with the ReFacto AF® FuseNGo device compared with their current treatment.2  

​​​​​​​Similar results were found in the survey of ease of reconstitution of factor VIII product, where ReFacto AF® FuseNGo device scored the same or higher than other devices for:3  

  • ​​​​​​​Ease of preparing clotting factor  
  • Ease of handling the device  
  • Ease of disposal of syringes and needles  
  • Ease of pushing down the syringe plunger  
  • Ease of storage  
Helix Image
The improvements from current treatment were significant (P<0.01 Wilcoxon signed ranks test) for all questions.

Adapted from Di Minno G et al. Patient Preference and Adherence 2019:13 233–240.2

​​​​​​​

Convenient

At baseline, the mean time to reconstitution of factor VIII product was 11 minutes. At follow-up, the reconstitution time was reduced to 6 minutes when patients were using the ReFacto AF® FuseNGo device.2  

Rapid reconstitution and administration

Positive responses to questions about effectiveness, convenience and overall satisfaction of the ReFacto AF® FuseNGo device approached or exceeded 90% in all cases.2 

98.8% of patients responded positively to both questions about overall satisfaction with the treatment delivery system.2

High levels of patient satisfaction

Patients receiving prophylactic factor VIII self-reported a treatment adherence >70% with ReFacto AF® FuseNGo.

High levels of treatment adherence  

†  An Italian study administered five questionnaires to patients with haemophilia A (from 21 centres; N=84 completed the study), including the specifically developed HemoPREF questionnaire for patient-related outcomes. Questionnaires were administered at baseline (when patients were using their current treatment) and at a final visit 3–6 months after the baseline visit, and after patients had experience of the ReFacto® FuseNGo delivery device.2  

‡  A cross-sectional survey conducted across 5 European countries (N=299) compared the ReFacto® FuseNGo device with four other methods of reconstituting factor VIII product.3 This survey looked at reconstitution and did not involve administration of the product. 

§  Patients who reported “always” or “often” adhering to treatment.  

Explore more

Administration and storage

ReFacto AF® is administered in the FuseNGo device, which allows all-in-one reconstitution of factor VIII.1

Find out more

Flexible dosing

No two days are the same. No two patients are the same. ReFacto AF® offers frequent, flexible dosing so your patients are covered for everyday life.1,4,5

Find out more

Monitoring

The use of the ReFacto AF® Laboratory Standard allows for consistent results regardless of assay type.

Find out more

Pfizer support for patients

Pfizer Ltd. is committed to helping patients manage their day-to-day lives.

Find out more

** This is an optional area where footnotes can live.

Heritage

ReFacto AF® (and ReFacto®) have more than 20 years’ experience in haemophilia A, building on a proud heritage in haemophilia care.1

Find out more

** This is an optional area where footnotes can live.

Contact us

Contact a member of the Pfizer haemophilia team.

Contact us

** This is an optional area where footnotes can live.


References
  1. ReFacto AF® Summary of Product Characteristics. For Great Britain, available here. For Northern Ireland, available here.
  2. Di Minno G et al. Patient Prefer Adherence 2019;13:233–240.  
  3. Cimino E et al. Patient Prefer Adherence 2014;8:1713–1720.  
  4. Shapiro AD et al. Haemophilia 2005;11:571–582.  
  5. Berntorp E, Andersson N. Semin Thromb Hemost. 2016;42:518–525.  
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
​​​​​​​Adverse events should also be reported to Pfizer Medical Information on 01304 616161.

PP-REF-GBR-0268. September 2021.

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021

Yes

No